AVITA Medical, Inc. (ASX:AVH – Get Free Report) insider Robert McNamara purchased 11,000 shares of the stock in a transaction dated Friday, March 7th. The stock was purchased at an average price of A$8.30 ($5.22) per share, with a total value of A$91,300.00 ($57,421.38).
Robert McNamara also recently made the following trade(s):
- On Friday, February 21st, Robert McNamara bought 10,000 shares of AVITA Medical stock. The shares were acquired at an average cost of A$10.09 ($6.35) per share, for a total transaction of A$100,900.00 ($63,459.12).
AVITA Medical Price Performance
The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.32 and a current ratio of 8.18. The stock has a market capitalization of $226.55 million, a PE ratio of -5.55 and a beta of 1.54.
About AVITA Medical
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
Further Reading
- Five stocks we like better than AVITA Medical
- 3 Warren Buffett Stocks to Buy Now
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- ETF Screener: Uses and Step-by-Step Guide
- Why Energy Transfer Belongs on Your Watchlist
- Comparing and Trading High PE Ratio Stocks
- Why Wayfair Stock May Be a Hidden Gem for Value Investors
Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.
